PASADENA, Calif., United States – May 5, 2026
Arrowhead Pharmaceuticals Inc. has entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals Inc. for ARO-PNPLA3, a clinical-stage RNA interference (RNAi) therapeutic targeting PNPLA3, a key genetic driver of metabolic dysfunction-associated steatohepatitis (MASH). The deal grants Madrigal full rights to develop, manufacture, and commercialize the therapy worldwide, with Arrowhead eligible for up to $1 billion in total milestone payments and tiered royalties, highlighting the high commercial and clinical value of precision genetic therapies in liver disease.
Precision Medicine Approach Targets High-Risk Patients
The ARO-PNPLA3 program is built on a genetically targeted approach, focusing on patients carrying the PNPLA3 I148M mutation, a well-established contributor to fat accumulation, liver inflammation, fibrosis, and cirrhosis. This mutation is particularly prevalent in Hispanic and Latino populations, making the therapy highly relevant for a genetically defined high-risk group often underserved in traditional treatment strategies. By leveraging its proprietary TRiM™ RNAi platform, Arrowhead Pharmaceuticals Inc.
aims to silence the expression of disease-causing genes directly in hepatocytes, representing a shift from symptom management to root-cause intervention in MASH, a disease with limited approved treatment options and rising global prevalence.
Phase 1 Data Demonstrates Strong Clinical Signal
Advertisement
Clinical data published in the The New England Journal of Medicine showed that ARO-PNPLA3 achieved up to 46% reduction in liver fat in patients who were homozygous for the PNPLA3 mutation, following a single dose, with effects observed as early as six weeks and sustained through 24 weeks. Importantly, the therapy demonstrated a favorable safety profile with no clinically meaningful adverse events, reinforcing its potential for further development.
However, the data also revealed a critical limitation: no significant effect was observed in heterozygous patients, meaning the therapy’s success is dependent on precise genetic patient selection, which could limit its overall market size but increase its effectiveness in targeted populations.
Strategic Deal Strengthens MASH Pipeline Expansion
Under the terms of the agreement, Madrigal Pharmaceuticals Inc. will make an upfront payment of $25 million, with Arrowhead eligible for up to $975 million in development, regulatory, and commercial milestones, along with royalties ranging from high-single digits to mid-teens. This deal reflects a strategic alignment, as Madrigal is already a leader in MASH therapeutics, making it better positioned to advance late-stage development and commercialization.
For Arrowhead, the partnership is part of a deliberate strategy to out-license high-potential programs outside its core focus, accelerating development timelines while reducing financial risk. The agreement also signals a broader industry trend toward genetic precision therapies and RNAi-based drug development, particularly in complex metabolic diseases where traditional approaches have struggled.
Source: Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals press release
